Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

Fung, Scott; Kwan, Peter; Fabri, Milotka; Horban, Andrzej; Pelemis, Mijomir; Hann, Hie-Won; GÜREL, SELİM; Caruntu, Florin; Flaherty, John; Massetto, Benedetta; Dinh, Phillip; Corsa, Amoreena; Subramanian, G.; McHutchison, John; Husa, Petr; Gane, Edward

doi:10.1053/j.gastro.2013.12.028

Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

Copy For Citation

Fung S., Kwan P., Fabri M., Horban A., Pelemis M., Hann H., ...More

GASTROENTEROLOGY, vol.146, no.4, pp.980-989, 2014 (SCI-Expanded)

Publication Type: Article / Article
Volume: 146 Issue: 4
Publication Date: 2014
Doi Number: 10.1053/j.gastro.2013.12.028
Journal Name: GASTROENTEROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.980-989
Keywords: HBV DNA, Hepatitis B e Antigen, Renal Function, Viral Suppression, BONE-MINERAL DENSITY, GENOTYPIC RESISTANCE, COMBINATION THERAPY, NUCLEOTIDE ANALOGS, ADEFOVIR DIPIVOXIL, TURNOVER MARKERS, NAIVE PATIENTS, ENTECAVIR, VIRUS, MANAGEMENT
Bursa Uludag University Affiliated: Yes

Abstract

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited.